CGONCG Oncology, Inc.
Price
+73%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
A flag to check, growing in the filings, the market undecided.
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec (cretostimogene), an investigational oncolytic immunotherapy with a dual mechanism of action designed both to eliminate cancer cells directly by selective replication and indirectly by activating an anti-tumor immune response, as a potential backbone therapy in a broad range of patients afflicted with bladder cancer.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
CG Oncology, Inc. (CGON) reported revenue of $1.2M in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $79M. For the full year FY2025, revenue was $4.0M (+255% year on year) and net income −$161M. Its largest product in Q2 2026 was Commercial And Development at $1.1M, 99% of the disclosed total, well ahead of License And Collaboration at 0.9%. The next results filing is expected around Nov 13, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026On August 6, 2026, the Company filed Amendment No. 2 to Prospectus (the “Amendment No. 2”) with the Securities and Exchange Commission (the “SEC”) for the offer and sale of shares of its common stock, par value $0.0001 per share (the “Shares”), pursuant to that certain Open Market Sale Agreement, dated March 28, 2025 …Earnings release · Form 8-K
- May 26, 2026Bellete Separation On May 20, 2026, CG Oncology, Inc. (the “Company”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.Director or officer change · Form 8-K
- Apr 13, 2026Appointment of Chief Financial Officer On April 13, 2026, CG Oncology, Inc. (the “Company”) appointed Jim DeTore as the Company’s Chief Financial Officer.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $1.2MThe company’s own SEC segment disclosure.
- Commercial And Development$1.1M99%
- License And Collaboration$10.0K1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry